Stay updated on Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial

Sign up to get notified when there's something new on the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision tag on the page was updated to v3.6.3, replacing the previous v3.6.0. This reflects a new page version without altering the study details presented.
    Difference
    0.0%
    Check dated 2026-06-30T01:26:29.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The study page now shows recruitment closed with 'No longer looking for participants'. New helper sections were added (How to Read a Study Record, Common Questions, How to Join a Study), the Intervention/Treatment header was updated, and the page revision updated from v3.5.5 to v3.6.0.
    Difference
    0.4%
    Check dated 2026-06-15T21:57:42.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The page shows a platform revision from v3.5.4 to v3.5.5, indicating a small update to the site that does not change the study details.
    Difference
    0.0%
    Check dated 2026-06-08T17:53:18.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    The revision label on the page updated from v3.5.3 to v3.5.4, indicating a software update to the site's interface.
    Difference
    0.0%
    Check dated 2026-05-18T13:25:46.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    The page’s footer revision indicator was updated from v3.5.0 to v3.5.3, reflecting a change in the site/version display rather than any study information.
    Difference
    0.0%
    Check dated 2026-04-27T07:32:06.000Z thumbnail image
  7. Check
    90 days ago
    Change Detected
    Summary
    The study results section now includes posted results data (ORR by RECIST v1.1 with 18-month follow-up) and related dates/documents, and Cohort 3 has been renamed from 'Safety and Tolerability' to 'Tolerability' with a 100-day dosing assessment.
    Difference
    2%
    Check dated 2026-04-05T16:47:43.000Z thumbnail image

Stay in the know with updates to Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page.